Edwards Lifesciences Securities Class Action Settlement

Investors who bought or otherwise acquired Edwards Lifesciences Corporation (NYSE: EW) common stock between February 6, 2024 and July 24, 2024 may qualify for a pro rata share of a $39,000,000 securities class action settlement. Claim forms must be submitted online or postmarked by December 2, 2026. Before you spend time on the form, check three things that decide most claims: shares sold before the close of trading on July 24, 2024 have a Recognized Loss of $0.00 under the Plan of Allocation; Edwards stock held through an Edwards ERISA-covered employee benefit plan must be left off the claim entirely; and nothing is paid at all if your distribution calculates below $10.00. This is an investor case about the company's TAVR heart-valve guidance, not a patient or medical-device claim, and it is separate from the Edwards shareholder derivative and ERISA matters, whose claims the release specifically carves out. Brokerage documentation is required for every transaction you list.

Do I Qualify?

You may be eligible if:

• You may qualify if you purchased or otherwise acquired Edwards Lifesciences Corporation common stock, traded on the New York Stock Exchange under the ticker EW, at any point from February 6, 2024 through the close of trading on July 24, 2024, inclusive, and were damaged thereby. Being in the Settlement Class is not the same as having a payable claim, and the gap between the two is unusually wide in this case. Shares bought and sold entirely inside the class period produce a Recognized Loss Amount of $0.00, because the Plan of Allocation only recognizes losses on shares still held when the alleged corrective disclosure hit the price on July 25, 2024 — a trader who was in and out of EW during the spring of 2024 is a class member who collects nothing. Edwards employees and other participants in an Edwards employee benefit plan covered by ERISA are told to exclude their plan shares from the Claim Form and to list only Edwards common stock they bought outside the plan, so plan-held EW does not count toward a claim here. Option contracts are not eligible securities, though common stock acquired or disposed of by exercising an option counts, using the exercise date and exercise price. Short sales and the purchases covering them carry a Recognized Loss of zero. Shares still held after the class period are measured against the statutory 90-day look-back: the mean closing price for EW from July 25 through October 22, 2024 was $66.77, and a still-held share's claim cannot exceed the purchase price minus that figure. Excluded from the Class are Edwards and CEO Bernard J. Zovighian, their successors and assigns, the past and current executive officers and directors of Defendants including the three Former Individual Defendants, the Immediate Family Members of those individuals, any entity in which an excluded person has or had a direct or controlling ownership interest, and the legal representatives, heirs, successors-in-interest and assigns of any of them — along with anyone whose exclusion request is received by December 2, 2026 and accepted by the Court.

Documentation is mandatory for every transaction you report. The Claim Form calls for a schedule of your Edwards common stock holdings and transactions supported by records such as brokerage account statements or trade confirmations, and the notice states that the Parties and the Claims Administrator do not have information about your transactions in Edwards common stock. Keep or request from your broker the statements covering your Edwards holdings as of the opening of trading on February 6, 2024 and every purchase, acquisition and sale through the close of trading on October 22, 2024 — the LIFO matching and the 90-day look-back both reach past the end of the class period, so an incomplete schedule can undercut a claim even when every class-period trade is listed. Do not include Edwards common stock held through an Edwards ERISA-covered employee benefit plan. The Court has reserved jurisdiction to allow, disallow or adjust any claim on equitable grounds. The settlement website is the source for the Claim Form, the Stipulation, the Plan of Allocation and Lead Counsel's fee motion, which is due to be filed by November 11, 2026.

What Happened?

Lead Plaintiffs City of Fort Lauderdale Police & Firefighters' Retirement System and Louisiana Sheriffs' Pension & Relief Fund sued Edwards Lifesciences Corporation and its Chief Executive Officer, Bernard J. Zovighian, in the U.S. District Court for the Central District of California, in Patel v. Edwards Lifesciences Corp., No. 8:24-cv-02221-AH-KES, filed October 14, 2024. The complaint alleges materially false and misleading statements to investors about the growth prospects of Edwards' core product, its transcatheter aortic valve replacement (TAVR) platform. The alleged truth reached the market with the company's July 24, 2024 results and revised TAVR guidance, and the Plan of Allocation measures the stock's reaction the following trading day. On September 19, 2025, the court allowed the core Section 10(b) fraud claim to proceed against Edwards and Zovighian while dismissing the claims against three other former executives, describing the question of Zovighian's intent as a very close one. After discovery focused on that issue, the parties accepted a mediator's recommendation of $39,000,000 following an April 20, 2026 session and signed the Stipulation and Agreement of Settlement on July 1, 2026. Judge Anne Hwang granted preliminary approval on August 3, 2026, and notice went out under an order dated August 24, 2026. Edwards and Zovighian expressly deny all claims and allegations of wrongdoing; the settlement is not an admission of liability or a finding on the merits. The release does not cover claims asserted in any related ERISA or shareholder derivative action, including In re Edwards Lifesciences Corp. Derivative Litigation, No. 8:24-cv-02822 (C.D. Cal.). The final approval hearing is set for December 16, 2026 at 1:30 p.m. Pacific Time in Courtroom 9C of the Felicitas and Gonzalo Mendez United States Courthouse in Los Angeles, and the notice warns that the date or format can change without further mailed notice. The Court has not yet approved the settlement, and no payment date has been announced — distributions follow only final approval, the resolution of any appeals and the completion of claims processing.

How to File Your Claim

1. File online at EdwardsLifesciencesSecuritiesLitigation.com, the official site run by court-approved Claims Administrator Kroll Settlement Administration, or mail the completed Claim Form to the address printed on the form (Edwards Lifesciences Securities Litigation, c/o Kroll Settlement Administration) — submitted online or postmarked if mailed, no later than December 2, 2026. A Claim Form comes with the mailed notice, can be downloaded from the settlement website, or can be requested by calling the administrator toll-free at 1-833-930-0555 or emailing info@EdwardsLifesciencesSecuritiesLitigation.com. Every transaction you list must be supported by documentation such as brokerage account statements or trade confirmations
2. the notice states plainly that the Parties and the Claims Administrator do not have information about your transactions in Edwards common stock. Report more than the class period itself: because sales are matched to purchases on a Last In, First Out basis across February 6, 2024 through the close of trading on October 22, 2024, the claim schedule covers that longer window plus your Edwards holdings as of the opening of trading on February 6, 2024. Leave ERISA plan shares off the form entirely. If your broker or another nominee bought the shares on your behalf, the notice requires that nominee to forward the Notice Packet to you or to give the administrator your contact details within seven calendar days. December 2, 2026 is also the date by which a request for exclusion must be received and by which any objection must be filed with the Court and received by counsel — the three deadlines fall on the same day here, so deciding to opt out or object cannot be deferred past the claim date.
3. Visit the official claim form: https://www.edwardslifesciencessecuritieslitigation.com/

How Much Will I Actually Get?

Pro rata cash from the $39,000,000 fund based on your Recognized Claim: your Recognized Claim divided by the total Recognized Claims of all Authorized Claimants, multiplied by the Net Settlement Fund. The notice estimates the average recovery at approximately $0.66 per eligible share before deduction of any Court-approved fees and expenses, taxes and administration costs, and estimates those deductions at approximately $0.17 per share if the Court awards the maximum requested — roughly $0.49 per share net. Both figures are the notice's own estimates, they assume every eligible investor files, and an individual Settlement Class Member may recover more or less. This is one payout path, not an election: every eligible share is common stock, and there is no separate track or menu of options to pick from. Per-share recovery is capped by the alleged inflation figure: the damages expert calculated $24.17 of estimated artificial inflation per share removed on July 25, 2024, and no share can produce a Recognized Loss Amount above that. Shares sold between July 25 and the close on October 22, 2024 take the least of $24.17, the purchase price minus the average closing price from July 25 through the sale date, or the purchase price minus the sale price. Shares still held at the close on October 22, 2024 take the lesser of $24.17 or the purchase price minus $66.77, the mean closing price over the statutory 90-day look-back period — so a purchase at or below $66.77 that was never sold yields nothing. THE $195,000 CAP APPLIES TO LITIGATION EXPENSES ONLY, NOT TO THE FEE REQUEST AND NOT TO THE SETTLEMENT AS A WHOLE: Lead Counsel will separately ask the Court for attorneys' fees of up to 25% of the Settlement Fund, which is up to about $9.75 million on a $39 million fund, and Notice and Administration Costs and Taxes also come out before the net is divided. Anyone reading $195,000 as the ceiling on what lawyers take from this fund is reading it wrong. Nothing is distributed where a claimant's Distribution Amount calculates to less than $10.00; that money is redistributed to claimants at or above $10.00.

Last reviewed: September 28, 2026 | Information verified from court records and official settlement documents.

Frequently Asked Questions